2017

1. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

   Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933